These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 21862569)
1. Genetic predictors of controlled ovarian hyperstimulation: where do we stand today? Altmäe S; Hovatta O; Stavreus-Evers A; Salumets A Hum Reprod Update; 2011; 17(6):813-28. PubMed ID: 21862569 [TBL] [Abstract][Full Text] [Related]
2. Allelic estrogen receptor 1 (ESR1) gene variants predict the outcome of ovarian stimulation in in vitro fertilization. Altmäe S; Haller K; Peters M; Hovatta O; Stavreus-Evers A; Karro H; Metspalu A; Salumets A Mol Hum Reprod; 2007 Aug; 13(8):521-6. PubMed ID: 17540666 [TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics in ovarian stimulation--current concepts. Loutradis D; Vlismas A; Drakakis P; Antsaklis A Ann N Y Acad Sci; 2008 Apr; 1127():10-9. PubMed ID: 18443324 [TBL] [Abstract][Full Text] [Related]
4. Association of allelic combinations of FSHR gene polymorphisms with ovarian response. Desai SS; Achrekar SK; Paranjape SR; Desai SK; Mangoli VS; Mahale SD Reprod Biomed Online; 2013 Oct; 27(4):400-6. PubMed ID: 23953588 [TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in gonadotropin and gonadotropin receptor genes as markers of ovarian reserve and response in in vitro fertilization. La Marca A; Sighinolfi G; Argento C; Grisendi V; Casarini L; Volpe A; Simoni M Fertil Steril; 2013 Mar; 99(4):970-8.e1. PubMed ID: 23380184 [TBL] [Abstract][Full Text] [Related]
7. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Nardo LG; Gelbaya TA; Wilkinson H; Roberts SA; Yates A; Pemberton P; Laing I Fertil Steril; 2009 Nov; 92(5):1586-93. PubMed ID: 18930213 [TBL] [Abstract][Full Text] [Related]
8. Ovarian response to standard gonadotrophin stimulation for IVF is decreased not only in older but also in younger women in couples with idiopathic and male subfertility. Goverde AJ; McDonnell J; Schats R; Vermeiden JP; Homburg R; Lambalk CB Hum Reprod; 2005 Jun; 20(6):1573-7. PubMed ID: 15746195 [TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of controlled ovarian hyperstimulation: time to corroborate the clinical utility of FSH receptor genetic markers. Morón FJ; Ruiz A Pharmacogenomics; 2010 Nov; 11(11):1613-8. PubMed ID: 21121812 [TBL] [Abstract][Full Text] [Related]
10. Does day 3 luteinizing-hormone level predict IVF success in patients undergoing controlled ovarian stimulation with GnRH analogues? Orvieto R; Meltzer S; Rabinson J; Gemer O; Anteby EY; Nahum R Fertil Steril; 2008 Oct; 90(4):1297-300. PubMed ID: 18249369 [TBL] [Abstract][Full Text] [Related]
11. Molecular pathology of the FSH receptor: new insights into FSH physiology. Meduri G; Bachelot A; Cocca MP; Vasseur C; Rodien P; Kuttenn F; Touraine P; Misrahi M Mol Cell Endocrinol; 2008 Jan; 282(1-2):130-42. PubMed ID: 18248882 [TBL] [Abstract][Full Text] [Related]
12. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Fauser BC; Diedrich K; Devroey P; Hum Reprod Update; 2008; 14(1):1-14. PubMed ID: 18006561 [TBL] [Abstract][Full Text] [Related]
13. Effect of follicle-stimulating hormone receptor Asn680Ser polymorphism on the outcomes of controlled ovarian hyperstimulation: an updated meta-analysis of 16 cohort studies. Tang H; Yan Y; Wang T; Zhang T; Shi W; Fan R; Yao Y; Zhai S J Assist Reprod Genet; 2015 Dec; 32(12):1801-10. PubMed ID: 26481502 [TBL] [Abstract][Full Text] [Related]
14. Association of estrogen, progesterone and follicle stimulating hormone receptor polymorphisms with in vitro fertilization outcomes. Ganesh V; Venkatesan V; Koshy T; Reddy SN; Muthumuthiah S; Paul SFD Syst Biol Reprod Med; 2018 Aug; 64(4):260-265. PubMed ID: 29916276 [TBL] [Abstract][Full Text] [Related]
15. Repeated in vitro fertilization cycle attempts in patients undergoing controlled ovarian hyperstimulation with use of gonadotropin-releasing hormone antagonists. Rabinson J; Ashkenazi J; Homburg R; Meltcer S; Anteby EY; Orvieto R Fertil Steril; 2009 Apr; 91(4 Suppl):1473-5. PubMed ID: 18937940 [TBL] [Abstract][Full Text] [Related]
16. Role of treatment with ovarian stimulation and intrauterine insemination in women with unilateral tubal occlusion diagnosed by hysterosalpingography. Farhi J; Ben-Haroush A; Lande Y; Fisch B Fertil Steril; 2007 Aug; 88(2):396-400. PubMed ID: 17445812 [TBL] [Abstract][Full Text] [Related]
17. Polymorphism FSHR (-29G/A) as a genetic agent together with ESRI (XbaIG/A) in women with poor response to controlled ovarian hyperstimulation. Zamaniara T; Taheripanah R; Ghaderian SMH; Zamaniara E; Aghabozorgi SSA Hum Antibodies; 2017; 26(3):143-147. PubMed ID: 29526845 [TBL] [Abstract][Full Text] [Related]
18. Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating hormone or highly purified human menopausal gonadotropin. Grøndahl ML; Borup R; Lee YB; Myrhøj V; Meinertz H; Sørensen S Fertil Steril; 2009 May; 91(5):1820-30. PubMed ID: 18439596 [TBL] [Abstract][Full Text] [Related]
19. [Clinical outcome of patients with follicular development retardation by prolonged duration of gonadotropin administration for in vitro fertilization]. Chen SL; Sun L; Kong LH; Li L; Li J; Zhu L; Gao TM; Xing FQ Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):526-9. PubMed ID: 17983490 [TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of controlled ovarian hyperstimulation. de Castro F; Morón FJ; Montoro L; Real LM; Ruiz A Pharmacogenomics; 2005 Sep; 6(6):629-37. PubMed ID: 16143002 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]